Drug intelligence / Profile preview

Selonterra APP modulator

Development stage: Preclinical
Lead developer: Selonterra
Modality: Small Molecules
Administration: Oral

Overview

The Selonterra APP modulator is a small molecule therapeutic currently in the target validation stage for the treatment of familial Alzheimer's disease. Developed by Selonterra, the drug targets the Amyloid Precursor Protein (APP), a key protein involved in the formation of amyloid-beta plaques, which are a hallmark of Alzheimer's pathology. By modulating APP, the therapy aims to address the underlying genetic drivers of familial Alzheimer's disease, which is often caused by mutations in the APP gene or related processing enzymes. This program is part of Selonterra's broader pipeline focused on neurodegenerative diseases.

Other names: APP modulator

Targets

APOE4 (Apolipoprotein E4)

Beyond the preview

Go deeper on Selonterra APP modulator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selonterra APP modulator.

Explore the full profile